
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical has demonstrated strong performance in console sales for Q3, surpassing expectations even with a major order deferred to the following quarter, indicating robust demand for its dialysis technology. The company is actively implementing cost reduction and efficiency initiatives aimed at improving service margins and reaching its longer-term gross margin target of 50%, with Q3 gross margins already showing steady improvement in the high-30s for FY25. Furthermore, Outset Medical is effectively managing its cash burn, tracking toward a target of less than $50 million in 2025, which is complemented by an expanding consumables ordering trend and a growing average order size in its Tablo pipeline.
Bears say
Outset Medical Inc. has lowered its full-year revenue guidance by approximately $7 million due to delays in enterprise deal timing and a reported sales miss in Q3, primarily driven by weak consumables revenue. Despite solid console revenue, the significant dip in consumable sales, particularly from acute care customers, suggests instability in what is typically a reliable revenue stream. Additionally, concerns regarding the new sales leadership and the impact of anticipated delayed enterprise deals into 2026 further contribute to a negative outlook for the company’s stock performance.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares